Clinical Trial Update: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating switching to raltegravir to reduce liver fibrosis progression in HIV and Hepatitis C co-infected patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Human Immunodeficiency Virus Infection
• Liver Fibrosis

Drugs mentioned

• Raltegravir (Isentress) (raltegravir)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: HIV, Hepatitis C | Phase 2 | Status: COMPLETED